Quo vadis nateglinide? Ten-year perspective

Bibliography

• Starlix (nateglinide): Product information, revised July 2008. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/Starlix.pdf
   Google Scholar
• Kikuchi M, Kosaka K, and the study group. Reduced postprandial hyperglycemia by A-4166 compared to voglibose in NIDDM subjects in Japan. Diabetes 1997;46:333A
   Web of Science ®Google Scholar
• Levien TL, Baker DE, Campbell RK, White JR. Nateglinide therapy for type 2 diabetes mellitus. Ann Pharmacother 2001;35:1426-34
   PubMed Web of Science ®Google Scholar
• Dunn CJ, Faulds D. Nateglinide. Drugs 2000;12:607-15
   Google Scholar
• Norman P, Rabasseda X. Nateglinide: a structurally novel insulin secretion agent. Drugs Today 2001;37(Suppl F):1-16
   Google Scholar
• Fujita T, Seto Y, Kondo N, Studies on the N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166) receptor in HIT cells T-15 cells. Displacement of [3H]glibenclimide. Biochem Pharmacol 1996;52:407-11
   PubMed Web of Science ®Google Scholar
• Hu S, Wang S, Fanelli B, Pancreatic ß-cell KATP Channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 2000;293:444-52
   PubMed Web of Science ®Google Scholar
• Fujitani S, Yada T. A novel D-phenylalanine-derivative hypoglycemic agent A-4166 increases cytosolic free Ca2+ in rat pancreatic β-cells by stimulating Ca2+ influx. Endocrinology 1994;134:1395-400
   PubMed Web of Science ®Google Scholar
• Lins L, Brasseur R, Malaisse WJ. Conformational analysis of non-sulfonylurea hypoglycaemic agents of the meglitinide family. Biochem Pharmacol 1995;50:1879-84
   PubMed Web of Science ®Google Scholar
• Lins L, Brasseur R, Malaisse WJ. Conformational analysis of the calcium complexes formed by meglitinide analogs. Res Commun Mol Pathol Pharmacol 1995;90:153-64
   PubMedGoogle Scholar
• Jijakli H, Ulussoy S, Malaisse WJ. Dynamics of the cationic and secretory responses to A-4166 in perifused pancreatic islets. Fundam Clin Pharmacol 1997;11:300-4
   PubMed Web of Science ®Google Scholar
• Malaisse WJ. Stimulation of insulin release by D-glucose in depolarized pancreatic islets. Cell Signal 1997;9:265-8
   PubMed Web of Science ®Google Scholar
• Morimoto S, Mokuda O, Sakamoto Y. Ay-4166 increases the sensitivity of insulin secretion to glucose in isolated perfused rat pancreas. Horm Metab Res 1998;30:77-9
   PubMed Web of Science ®Google Scholar
• Hu S, Wang S, Dunning BE. Tissues electivity of antidiabetic agent nateglinide: Study on cardiovascular and ß-cell K (ATP) channels. J Pharmacol Exp Ther 1999;291:1372-9
   PubMed Web of Science ®Google Scholar
• Ikenoue T, Okazaki K, Fujitani S, Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine, on postprandial blood glucose excursion: comparison with voglibose and glibenclaimide. Biol Pharm Bull 1997;20:354-9
   PubMed Web of Science ®Google Scholar
• Ikenoue T, Akiyoshi Fujitani S, Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166). Br J Pharmacol 1997;120:137-45
   PubMed Web of Science ®Google Scholar
• Hirose H, Maruyama H, Seto Y, Effects of a D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic alpha- and β-cells: comparative study with glibenclimide. Pharmacology 1995;50:175-81
   PubMed Web of Science ®Google Scholar
• Kamijima M, Ushimaru T, Kinoshita K, Reproductive and developmental toxicity study of AY4166 in rats administered orally during fetal organogenesis (Seg II (revised report). Jpn Pharmacol Ther 1999;27:129-49
   Google Scholar
• Nagashima Y, Akai H, Ide M, A 12-month repeated oral dose toxicity study of AY4166 in beagle dogs (revised report). Jpn Pharmacol Ther 1999;27:91-118
   Google Scholar
• Oazaki S, Ikezaki S, Yamazaki S, A 12-month repeated oral dose toxicity study of AY4166 in rats (revised report). Jpn Pharmacol Ther 1999;27:75-89
   Google Scholar
• Kamijima M, Morimoto K, Kinoshiota K, Reproductive and developmental toxicity study of AY4166 in rats administered orally during the perinatal and lactation period (Seg III) (revised report). Jpn Pharmacol Ther 1999;27:151-67
   Google Scholar
• Okuyama M, Momose Y, Kuroiwa H, Pharmacokinetic studies of AY4166 (3) – Absorption, distribution and excretion in dogs. Jpn Pharmacol Ther 1997;25(Suppl 1):207-17
   Google Scholar
• Shima Y, Mihara R, Suzuki M, Pharmacokinetic studies of AY4166 (1) – Absorption, distribution and excretion in rats after singly administration. Jpn Pharmacol Ther 1997;25(Suppl 1):181-94
   Google Scholar
• Karara AH, Dunning BE, McLeod JF. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol 1999;39:172-9
   PubMed Web of Science ®Google Scholar
• Weaver MI, Orwig BA, Rodriguez LC, Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos 2001;29:415-21
   PubMed Web of Science ®Google Scholar
• Devineni D, McLeod J, Prasad P, The pharmacokinetics and pharmacodynamics of nateglinide in relation to meal timing in non-insulin dependent diabetes mellitus (NIDDM) subjects. AAPS PharmSciTech 1998;1:S-143
   Google Scholar
• Kikuchi M. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Diabetes Med 1996;13(Suppl 6):S151-5
   Google Scholar
• Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000;23:349-53
   PubMed Web of Science ®Google Scholar
• Choudhury S, Hirschberg Y, Filipek R, Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. J Clin Pharmacol 2000;40:634-40
   PubMed Web of Science ®Google Scholar
• Takesada H, Matsuda K, Ohtake R, Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent. Bioorg Med Chem 1996;4:1771-81
   PubMed Web of Science ®Google Scholar
• Whitelaw DC, Clark PM, Smith JM, Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in type 2 diabetes mellitus. Diabetes Med 2000;17:225-9
   PubMed Web of Science ®Google Scholar
• Uchino N, Niwa M, Shimizu T, Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue. Endocr J 2000;47:639-41
   PubMed Web of Science ®Google Scholar
• Walter YH, Spratt DI, Garreffa S, McLeod JF. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus. Eur J Clin Pharmacol 2000;56:129-33
   PubMed Web of Science ®Google Scholar
• Keilson L, Mather S, Walter YH, Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85:1081-6
   PubMed Web of Science ®Google Scholar
• Kahn SE, Montgomery B, Howell W, Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001;86:5824-9
   PubMed Web of Science ®Google Scholar
• Ligueros-Saylan M, Khalilieh S, Lee J, Nateglinide has a low hypoglycemic potential in a missed-meal situation. Diabetes 2000;49(Suppl 1):A360
   Google Scholar
• Schweizer A, Ball M, Owens DR, Comparison of the postprandial glucose and insulin profiles with nateglinide and gliclazide in type 2 diabetic patients. Br J Diabetes Vasc Dis 2002;2:228-32
   Google Scholar
• Gribble FM, Manley SE, Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care 2001;24:1221-5
   PubMed Web of Science ®Google Scholar
• Kalbag JB, Walter YH, Nedelman JR, McLeod JF. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglanide and placebo. Diabetes Care 2001;24:73-7
   PubMed Web of Science ®Google Scholar
• Saloranta C, Hershon K, Ball M, Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 2002;87:4171-6
   PubMed Web of Science ®Google Scholar
• Horton ES, Clinkingbeard C, Gatlin M, Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660-5
   PubMed Web of Science ®Google Scholar
• Marre M, Van Gaal L, Usadel K-H, Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab 2002;4:177-86
   PubMed Web of Science ®Google Scholar
• Raskin P, Klaff L, McGill J, Efficacy and safety of combination therapy. Repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003;26:2063-8
   PubMed Web of Science ®Google Scholar
• Hollander PA, Schwartz SL, Gatlin MR, Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24:983-8
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000;23:202-7
   PubMed Web of Science ®Google Scholar
• Del Prato S, Heine RJ, Keilson L, Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care 2003;26:2075-80
   PubMed Web of Science ®Google Scholar
• Inoue T, Shibahara N, Miyagawa K, Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003;60:90-5
   PubMed Web of Science ®Google Scholar
• Holmes D, Raccah D, Escobar-Jimenez F, Standl E. Targeting postprandial hyperglycemia to achieve glycemic control in patients with type 2 diabetes: a comparison of nateglinide and acarbose. Abstract presented at Eur Assoc Study Diab, Glasgow, 2001
   Google Scholar
• Fonseca V, Grunberger G, Gupta S, Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. Diabetes Care 2003;26:1685-90
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Davidson JA, Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
   PubMed Web of Science ®Google Scholar
• Devineni D, Walter YH, Smith HT, Pharmacokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol 2003;43:163-70
   PubMed Web of Science ®Google Scholar
• Twaites B, Wilton LV, Layton D, Shakir SA. Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study. Acta Diabetol 2007;44:233-9
   PubMed Web of Science ®Google Scholar
• Krum H, McMurray JJV, Horton E, Baseline characteristics of the nateglinide and valsartan impaired glucose tolerance outcomes research (NAVIGATOR) trial population: comparing with other diabetes prevention trials. Cardiovasc Ther 2010;28:124-32
   PubMed Web of Science ®Google Scholar
• Califf RM, Boolell M, Haffner SM, Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Am Heart J 2008;156:623-32
   PubMed Web of Science ®Google Scholar
• Holman RR, Haffner SM, McMurray JJ, Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-76
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Clinical Practice Recommendations. Diabetes Care 2011;34(Suppl 1):S11-61
   PubMed Web of Science ®Google Scholar
• Ceriello A. Postprandial hyperglycemia and diabetes complications is it time to treat? Diabetes 2005;54:1-7
   PubMed Web of Science ®Google Scholar
• Dunn C, Curran MP. Inhaled human insulin (Exubera): a review of its use in adult patients with diabetes mellitus. Drugs 2006;66:1013-32
   PubMed Web of Science ®Google Scholar
• Bunck MC, Diamant M, Corner A. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients. A randomized, controlled trial. Diabetes Care 2009;32:762-8
   PubMed Web of Science ®Google Scholar
• Borg R, Kuenen JC, Carstensen B, HbA1c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-derived average glucose (ADAG) study. Diabetologia 2011;54:69-72
   PubMed Web of Science ®Google Scholar
• Raz I, Wilson PWF, Strojek K, Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-6
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
   PubMed Web of Science ®Google Scholar